Pharmaceutical

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…

10 months ago

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases…

10 months ago

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch…

10 months ago

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment…

10 months ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD…

10 months ago

Harvard Bioscience Announces Fourth Quarter 2023 Financial Results

Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating…

10 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of…

10 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…

10 months ago

LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million

Up to $3.5 M in cash proceedsUp to $4.5 M in debts conversion Proceeds to be used to further expand…

10 months ago

BioNTech Announces Planned Retirement of Sean Marett

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean…

10 months ago